Source: The Next Web
Generare, a Paris-based techbio company, uses AI to screen microbial genomes for novel small molecules and claims to have characterized more novel molecules in 2025 than the entire rest of the field combined. The company raised a Series A led by Alven and Daphni, positioning itself as a leader in computational discovery of bioactive compounds.